JP2009102341A5 - - Google Patents

Download PDF

Info

Publication number
JP2009102341A5
JP2009102341A5 JP2008309431A JP2008309431A JP2009102341A5 JP 2009102341 A5 JP2009102341 A5 JP 2009102341A5 JP 2008309431 A JP2008309431 A JP 2008309431A JP 2008309431 A JP2008309431 A JP 2008309431A JP 2009102341 A5 JP2009102341 A5 JP 2009102341A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rapamycin
hydroxy
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008309431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009102341A (ja
JP5160386B2 (ja
Filing date
Publication date
Priority claimed from GBGB0123400.4A external-priority patent/GB0123400D0/en
Application filed filed Critical
Publication of JP2009102341A publication Critical patent/JP2009102341A/ja
Publication of JP2009102341A5 publication Critical patent/JP2009102341A5/ja
Application granted granted Critical
Publication of JP5160386B2 publication Critical patent/JP5160386B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008309431A 2001-09-28 2008-12-04 コロイド状二酸化ケイ素を含んでなる医薬組成物 Expired - Lifetime JP5160386B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0123400.4 2001-09-28
GBGB0123400.4A GB0123400D0 (en) 2001-09-28 2001-09-28 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003532038A Division JP2005507897A (ja) 2001-09-28 2002-09-27 コロイド状二酸化ケイ素を含んでなる医薬組成物

Publications (3)

Publication Number Publication Date
JP2009102341A JP2009102341A (ja) 2009-05-14
JP2009102341A5 true JP2009102341A5 (enExample) 2011-12-08
JP5160386B2 JP5160386B2 (ja) 2013-03-13

Family

ID=9922916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003532038A Withdrawn JP2005507897A (ja) 2001-09-28 2002-09-27 コロイド状二酸化ケイ素を含んでなる医薬組成物
JP2008309431A Expired - Lifetime JP5160386B2 (ja) 2001-09-28 2008-12-04 コロイド状二酸化ケイ素を含んでなる医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003532038A Withdrawn JP2005507897A (ja) 2001-09-28 2002-09-27 コロイド状二酸化ケイ素を含んでなる医薬組成物

Country Status (30)

Country Link
US (4) US20040254210A1 (enExample)
EP (2) EP2193788B1 (enExample)
JP (2) JP2005507897A (enExample)
KR (1) KR100626785B1 (enExample)
CN (3) CN101912392A (enExample)
AR (2) AR036643A1 (enExample)
AT (1) ATE485813T1 (enExample)
BR (2) BRPI0212922B1 (enExample)
CA (1) CA2458455C (enExample)
CO (1) CO5390072A1 (enExample)
CY (2) CY1111119T1 (enExample)
DE (1) DE60238131D1 (enExample)
DK (2) DK1432408T3 (enExample)
EC (1) ECSP024323A (enExample)
ES (2) ES2560106T3 (enExample)
GB (1) GB0123400D0 (enExample)
HU (1) HU229991B1 (enExample)
IL (2) IL160498A0 (enExample)
MX (1) MXPA04002814A (enExample)
MY (1) MY150060A (enExample)
NO (1) NO333892B1 (enExample)
NZ (2) NZ542273A (enExample)
PE (1) PE20030602A1 (enExample)
PL (1) PL209704B1 (enExample)
PT (2) PT2193788E (enExample)
RU (1) RU2322970C2 (enExample)
SI (1) SI1432408T1 (enExample)
TW (1) TWI242449B (enExample)
WO (1) WO2003028705A1 (enExample)
ZA (1) ZA200401300B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
UA81265C2 (en) * 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
AU2003272964A1 (en) * 2002-10-09 2004-05-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN105770871A (zh) * 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
CN101444494B (zh) * 2008-12-31 2011-03-30 江苏大学 难溶性药物高效长效缓释制剂及其制法
CN101439025B (zh) * 2008-12-31 2011-05-11 江苏大学 一种水飞蓟素高效长效制剂及其制法
CN101444503B (zh) * 2008-12-31 2011-02-02 江苏大学 一种水飞蓟宾高效长效制剂及其制法
PL2389070T3 (pl) * 2009-01-21 2014-01-31 Mylan Inc Preparaty węglanu lantanu ulegające rozpadowi
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
DE102011052396A1 (de) * 2011-08-04 2013-02-07 Gelita Ag Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung
KR101151890B1 (ko) * 2011-08-11 2012-05-31 동아제약주식회사 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
EP2763663B1 (en) 2011-10-06 2017-12-27 Novartis AG Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
CN103610646B (zh) * 2013-12-05 2015-07-15 江苏奥赛康药业股份有限公司 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016135740A1 (en) 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
WO2017204215A1 (ja) 2016-05-27 2017-11-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
JP2020500930A (ja) 2016-11-23 2020-01-16 ノバルティス アーゲー エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
CN110831582B (zh) 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
CN108125918B (zh) * 2018-01-12 2020-06-23 杭州中美华东制药有限公司 依维莫司药物组合物
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US20230201234A1 (en) * 2020-06-01 2023-06-29 Shilpa Medicare Ltd Fast dispersible pharmaceutical composition comprising capecitabine
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022219652A1 (en) * 2021-04-17 2022-10-20 Bdr Pharmaceuticals International Private Limited Novel sublingual pharmaceutical formulations for everolimus
CN119523923A (zh) * 2024-11-21 2025-02-28 华中药业股份有限公司 一种左炔诺孕酮片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US4920102A (en) 1988-04-18 1990-04-24 Eli Lilly And Company Method for treating gastrointestinal disorders
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
ATE173931T1 (de) 1991-07-03 1998-12-15 Upjohn Co Tabletten mit hohem gehalt an colestipolhydrochlorid
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
TW473393B (en) * 1996-02-29 2002-01-21 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet and production thereof
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
AU2308097A (en) * 1996-04-26 1997-11-19 Shionogi & Co., Ltd. Rapid-release s1452 tablets
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
NZ335737A (en) 1996-11-12 2000-09-29 Pharmacia & Upjohn Ab Compact member comprising a plurality of porous cellulose matrices (PCMs)
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
TR199903065T2 (xx) 1997-06-13 2000-09-21 American Home Products Corporation Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
AU749623B2 (en) 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU2944700A (en) * 1999-03-15 2000-10-04 Kaken Pharmaceutical Co., Ltd. Quickly disintegrating tablets and process for producing the same
FR2793690B1 (fr) 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
DK1179342T3 (da) * 1999-05-21 2006-07-31 Kissei Pharmaceutical Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl

Similar Documents

Publication Publication Date Title
JP2005507897A5 (enExample)
AR097341A2 (es) Composición farmaceutica que comprende una dispersión de macrólidos sólidos, y un proceso para producir una tableta dispersable que contiene un macrólido
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
EP4512474A3 (en) Solid oral nicotine formulation
MY147641A (en) Fast release paracetamol tablets
WO2004100857A3 (en) Highly plastic granules for making fast melting tablets
NZ610729A (en) Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2006128121A3 (en) Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
IL192374A0 (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
NZ592325A (en) Extended release oral acetaminophen/tramadol dosage form
JP2009280621A5 (enExample)
TW200621268A (en) Antimicrobial copolymers and uses thereof
NZ610701A (en) Once daily formulation of lacosamide
EP3272337A3 (en) Tablets
MX343358B (es) Tabletas de acetato de ulipristal.
EP1980272A3 (en) Orally-disintegrating tablet and manufacturing method thereof
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
IL207928A (en) Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity
WO2003047552A3 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
GEP20125636B (en) Slow-release formulation based on glycogen and alginate association
JP2011516544A5 (enExample)
TW200637537A (en) Pharmaceutical composition containing sibutramine free base and manufacturing method thereof
WO2010023690A3 (en) Prolonged release formulation of amisulpride
WO2008092219A3 (en) Pharmaceutical composition comprising tramadol and ketoprofen